CTLA4 and neoplasm: Firstly, the localized and sustained release of checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies) from the hydrogel depot maintains high therapeutic concentrations within the tumor microenvironment (TME) while minimizing systemic exposure and associated toxicities [103].